Crescent Biopharma, Inc.
CBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,967 | $623 | $1,355 | $1,606 |
| - Cash | $133 | $153 | $6 | $11 |
| + Debt | $2 | $2 | $0 | $0 |
| Enterprise Value | $1,835 | $472 | $1,349 | $1,595 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$25 | -$21 | -$2 | -$5 |
| % Margin | – | – | – | – |
| Net Income | -$25 | -$22 | -$2 | -$7 |
| % Margin | – | – | – | – |
| EPS Diluted | -1,266.44 | -0.56 | -0.036 | -0.11 |
| % Growth | -226,050% | -1,442.7% | 67% | – |
| Operating Cash Flow | -$18 | -$22 | -$5 | -$4 |
| Capital Expenditures | -$1 | -$0 | $0 | $0 |
| Free Cash Flow | -$18 | -$22 | -$5 | -$4 |